Drugs / HSK46256
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT07695142 | Jul 2026 → Dec 2028 expected | — | Haisco Pharmaceutical Group Co., Ltd. | Not yet recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | HSK46256 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07695142 ↗ |
| Action | Inhibit | “a selective PARP1 inhibitor” NCT07695142 ↗ |
| Route | Oral | “Oral administration.” NCT07695142 ↗ |
| Target | PARP1 | “a selective PARP1 inhibitor” NCT07695142 ↗ |